Advanced Oncology Certified Nurse Practitioner (AOCNP) Certification Practice Test 2026 - Free AOCNP Practice Questions and Study Guide

Aromatase inhibitors are a class of medications that play a crucial role in the treatment of estrogen receptor-positive breast cancer, particularly in postmenopausal women. The primary mechanism of action for aromatase inhibitors is to reduce estrogen production in the body. They achieve this by inhibiting the aromatase enzyme, which is responsible for converting androgens (such as testosterone and androstenedione) into estrogens in peripheral tissues.

By lowering estrogen levels, these inhibitors effectively limit the hormone's availability to stimulate tumor growth, as many breast cancers are driven by estrogen. This reduction in estrogen can lead to a decrease in the size of existing tumors and a lower likelihood of recurrence following initial treatment.

In contrast, other potential mechanisms mentioned in the incorrect options, such as stimulating estrogen receptors or increasing progesterone levels, do not align with the pharmacological action of aromatase inhibitors. Enhancing tumor growth is entirely contrary to the therapeutic goal of these agents in oncology practice. Thus, the primary and correct answer regarding the function of aromatase inhibitors in breast cancer treatment is that they reduce estrogen production.